Carlyle to acquire life sciences investment firm Abingworth

11 April 2022

Global investment firm Carlyle (Nasdaq: CG) announced today that it has agreed to acquire Abingworth, a transatlantic life sciences investment firm with over $2 billion in assets under management (AUM), to bolster Carlyle’s leading global healthcare franchise and enter the biotech financing arena.

Today’s announcement demonstrates an extension of Carlyle’s long-term global commitment to leadership in healthcare in which it has invested over $22 billion across buyout and growth equity since inception.

This transaction will enable Carlyle to operate across the full risk-return spectrum of life sciences and healthcare investing, from venture capital to buyouts, and to continue Carlyle’s long-standing efforts to be an important part of the solution in healthcare.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK